News

Algocyte Proxima receives UAE regulatory clearance and begins an Abu Dhabi home-monitoring study with major hospital under authorisation of the Department of Health

Algocyte Proxima receives UAE regulatory clearance and begins an Abu Dhabi home-monitoring study with major hospital under authorisation of the Department of Health

Abu Dhabi, United Arab Emirates, 20 November 2026 — Oxford Immune Algorithmics (OIA), the company behind Algocyte, has received regulatory clearance for professional use in the United Arab Emirates from the Emirates Drug Establishment (EDE) for Algocyte Proxima. It is the first regulatory clearance for Algocyte Proxima outside the United Kingdom after achieving UKCA mark.

Alongside the clearance, a comprehensive research study and pilot approved by the Department of Health – Abu Dhabi will begin with Burjeel Medical City where authorities have already received two Algocyte Proxima devices for field deployment and nurse training has begun. The study will run in parallel to current clinical pathways for comparison purposes and will bring complete remote testing and monitoring into the homes of people living with chronic conditions as a future alternative.

The UAE has made digital health and care closer to home a national priority. Abu Dhabi in particular is investing in health innovation, data and research. That makes the country a natural place to show how near-patient testing can support people with long-term conditions.

“Regulatory clearance from the Emirates Drug Establishment and the start of this study with Burjeel Medical City are major steps for Algocyte. The UAE is leading on health innovation, and together we can show how remote testing at home, supervised by nurses, can give clinicians a fuller and more regular picture of patients with chronic conditions, even in the hottest months of the year.”
Hector Zenil, Founder and CEO of Algocyte & Associate Professor in Healthcare Engineering, King's College London

A study and pilot approved by the Department of Health – Abu Dhabi

Participants with chronic conditions will test themselves at home with Algocyte Proxima, with nurses supervising each test. Test results go straight to Algocyte TestHub, where in the future a care team will be able to review and release, building a longitudinal picture of each patient between hospital visits.

The Department of Health – Abu Dhabi regulates the healthcare sector in the Emirate of Abu Dhabi and oversees research involving patients there. Its approval of the study sets the clinical and ethical framework the pilot will follow.

Homes in the region can get very hot in summer, so the study will also track environmental factors, including room temperature in hot weather. The aim is to understand how Algocyte Proxima performs in real homes in the region, not just in controlled settings, and to inform how home testing can be offered safely across the Gulf.

Burjeel Medical City is a large tertiary hospital in Abu Dhabi and the flagship of Burjeel Holdings, one of the leading private healthcare providers in the region. It is known for complex and specialist care, including long-term care for people with chronic disease, and for adopting new medical technology. As the study partner, its clinicians and nurses will lead patient recruitment and supervise testing at home.

About the Emirates Drug Establishment & Algocyte Proxima

The Emirates Drug Establishment (EDE) is the UAE's federal regulator for medicines, medical devices and other health products. It aims to lead on both innovation and patient safety in the country, giving people in the UAE access to new health technologies while holding them to high safety standards.

Algocyte Proxima is a portable, AI-enabled haematology analyser. It was conceived, designed and made in Britain, received UKCA certification and was launched at the Royal Society of Medicine in London in July 2026. The Algocyte Connect App guides each step of the test, and the device sends results securely to the care team.

For people with chronic conditions, frequent medical tests often mean repeated trips to a clinic. Testing close to the patient can make monitoring more regular, more convenient and easier to fit into daily life.

In the pilot, Algocyte Proxima is the physical contact point of the Algocyte Ecosystem, with Algocyte TestHub with the future prospect to giving clinicians control over both a device fleet and their patients' results.

OIA has also signed with Capital Medical as its first distributor in the UAE and is exploring joint venture opportunities to bring the Algocyte Ecosystem to patients across the country.

About Oxford Immune Algorithmics

Oxford Immune Algorithmics Ltd (OIA) is a British healthcare technology company with roots in Oxford and London. It develops Algocyte, a platform that combines physical testing near the patient with AI to support more personalised, anticipatory care. Its products form the Algocyte Ecosystem, led by Algocyte Proxima, the portable blood testing device at its heart.

Algocyte was created by Oxford Immune Algorithmics, a company incubated by the University of Oxford, spun out from King's College London, with research from and studies conducted within the Cambridge and NHS ecosystems.

Algocyte Proxima is cleared for professional use in the United Arab Emirates, subject to regular compliance with EDE's applicable importation/exportation requirements, vigilance obligations and other relevant regulatory mandates.

← All news

Bring regular precision and predictive monitoring to users and patients.

See Algocyte in action.